Journal of Biological Chemistry · 2013 · 45 citations · 28 references
Life SciencesBiochemistryMolecular PharmaceuticsDrug DeliveryGlycobiologyProtein EngineeringFc EngineeringGlycoengineering Of AntibodiesGlycosylation PathwaysN-linked GlycosylationProtein GlycoengineeringProtein GlycosylationAntibody Glycosylation ControlFc Glycan OptimizationGlycosylation EngineeringHalf-life Extension EngineeringLife Extension
Human IgG is a bivalent molecule that has two identical Fab domains connected by a dimeric Fc domain. For therapeutic purposes, however, the bivalency of IgG and Fc fusion proteins could cause undesired properties. We therefore engineered the conversion of the natural dimeric Fc domain to a highly soluble monomer by introducing two Asn-linked glycans onto the hydrophobic C H 3-C H 3 dimer interface. The monomeric Fc (monoFc) maintained the binding affinity for neonatal Fc receptor (FcRn) in a pH-dependent manner. We solved the crystal structure of monoFc, which explains how the carbohydrates can stabilize the protein surface and provides the rationale for molecular recognition between monoFc and FcRn. The monoFc prolonged the in vivo half-life of an antibody Fab domain, and a tandem repeat of the monoFc further prolonged the half-life. This monoFc modality can be used to improve the pharmacokinetics of monomeric therapeutic proteins with an option to modulate the degree of half-life extension. Background: The bivalency of IgG and Fc fusion could cause undesired therapeutic properties. Results: We developed a stable monomeric Fc modality by N- glycosylation engineering, enabling the generation of crystal structure. Conclusion: The monomeric Fc prolonged the half-life of Fab domain through the interaction with neonatal Fc receptor. Significance: The monomeric Fc will be used for pharmacokinetics enhancement of biotherapeutics that require monovalent properties.
28
Enhanced antibody half-life improves in vivo activity
Jonathan Zalevsky, Aaron K. Chamberlain, Holly M. Horton et al. · Nature Biotechnology · 2010 · 644 citations · Full text
Enhancement of therapeutic protein in vivo activities through glycoengineering
Steve Elliott, Tony Lorenzini, Sheilah Asher et al. · Nature Biotechnology · 2003 · 516 citations